MICROBIOLOGY • IMMUNOLOGY BASICS FOR MICROBIOLOGY

Complement System

A cascade of serum proteins that bridges innate and adaptive immunity to destroy pathogens.

Historical Context & Motivation

The discovery of the complement system arose from a fundamental puzzle in late-nineteenth-century microbiology: serum from immunized animals could kill bacteria, yet heating the serum to 56 °C abolished this bactericidal activity while preserving the antibodies within it. This observation implied that a heat-labile factor in blood was required to complement the action of antibodies—hence the name. Understanding this system has since become central to immunology because complement sits at the intersection of innate defense and adaptive immunity, providing rapid, enzymatic amplification of antimicrobial responses long before adaptive effectors reach full strength.

1895
Jules Bordet Identifies 'Alexin'
Belgian immunologist Jules Bordet demonstrated that fresh serum contained a heat-labile bactericidal substance he called alexin, distinct from heat-stable antibodies. This was the first experimental evidence of the complement system.
1907
Paul Ehrlich Coins 'Complement'
Paul Ehrlich renamed Bordet's alexin as complement, emphasizing its role in complementing the action of antibodies. He proposed it as part of his broader side-chain theory of immunity.
1960s
Sequential Activation Cascade Mapped
Researchers including Müller-Eberhard and Nelson elucidated the classical pathway as a series of proteolytic cleavages from C1 through C9, revealing the ordered, enzymatic nature of complement activation.
1980s
Alternative and Lectin Pathways Characterized
The alternative pathway, initially described by Pillemer in the 1950s and later validated, was fully characterized alongside the discovery of the mannose-binding lectin (MBL) pathway, demonstrating that complement activation could proceed independently of antibodies.
2000s–Present
Complement in Disease and Therapy
Dysregulation of complement was linked to diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, and age-related macular degeneration. Eculizumab, a monoclonal antibody against C5, became a landmark complement-targeting therapeutic.

The central question that drove over a century of complement research was deceptively simple: how does the host generate a rapid, broadly effective antimicrobial response in the blood and tissues before the adaptive immune system mounts a specific reply? The answer—a tightly regulated cascade of more than 30 soluble and membrane-bound proteins—turns out to be one of the most elegant enzymatic amplification systems in biology. As we will explore, complement not only lyses pathogens directly but also opsonizes targets for phagocytosis, recruits inflammatory cells, and modulates adaptive immune responses.

Core Principles & Definitions

The complement system operates through a set of fundamental principles that govern its activation, amplification, and regulation. At its core, complement is a proteolytic cascade: inactive precursor proteins (zymogens) circulate in the blood and are sequentially cleaved to generate active enzymes and bioactive fragments. Each activated component catalyzes the cleavage of many molecules of the next component, creating exponential amplification. Because this amplification is powerful enough to damage host cells, a parallel system of regulatory proteins ensures that complement activity remains focused on foreign surfaces and is rapidly attenuated on self tissue.

1

Three Initiation Pathways

Complement can be triggered via the classical (antibody-dependent), lectin (pattern recognition), or alternative (spontaneous hydrolysis) pathways. All three converge on C3 convertase formation.
2

Convergence at C3

Regardless of initiation pathway, the cascade converges at the cleavage of C3 into C3a (anaphylatoxin) and C3b (opsonin). C3b deposition on surfaces is the central event of complement activation.
3

Enzymatic Amplification

A single C3 convertase can cleave hundreds of C3 molecules in minutes. This amplification loop ensures rapid coating of pathogen surfaces with C3b for phagocyte recognition and downstream lysis.
4

Effector Functions

Complement produces three main effector outcomes: opsonization (C3b tagging), inflammation (C3a/C5a recruit leukocytes), and lysis via the membrane attack complex (MAC).
5

Host Protection via Regulators

Host cells express surface regulators such as decay-accelerating factor (DAF/CD55) and CD59 that prevent complement-mediated damage. Pathogens lack these regulators, making them selectively vulnerable.
KEY TAKEAWAY
Think of complement like a series of dominoes arranged in three separate starting lines that all feed into a single main track. Knocking over any starting domino (classical, lectin, or alternative pathway) sets off the central cascade (C3 cleavage), which then splits into multiple outcome tracks—tagging intruders for removal, summoning reinforcements, and punching holes in enemy walls. Meanwhile, your own cells carry shields (regulatory proteins) that catch the dominoes before they reach them, keeping you safe from friendly fire.

Visual Overview of the Three Pathways

The three initiation pathways—classical (left), lectin (center), and alternative (right)—each generate a C3 convertase that cleaves C3 into C3a and C3b. Downstream, the cascade produces three major effector outcomes: opsonization, MAC-mediated lysis, and anaphylatoxin-driven inflammation.

The diagram above captures the organizational logic of the complement system. Notice that the classical and lectin pathways generate identical C3 convertases (C4b2a), whereas the alternative pathway produces a structurally distinct convertase (C3bBb). Despite this difference, both convertases perform the same catalytic function: they cleave C3 into C3a and C3b. This convergence at C3 is what allows a single downstream cascade—assembly of the C5 convertase and ultimately the membrane attack complex—to serve all three pathways. The alternative pathway also functions as a built-in amplification loop: newly deposited C3b molecules recruit Factor B and Factor D to form additional C3bBb convertases, creating a positive feedback cycle that rapidly coats pathogen surfaces.

Pathway Mechanisms in Detail

Classical Pathway

The classical pathway is initiated when the C1 complex binds to antigen–antibody complexes. The C1 complex consists of one molecule of C1q associated with two molecules each of C1r and C1s (written C1q:C1r2:C1s2). C1q has six globular heads that recognize the Fc regions of IgG or IgM bound to antigen; at least two heads must be engaged for stable binding, which explains why pentameric IgM is far more efficient than IgG at activating this pathway. Binding triggers autoactivation of C1r, which then cleaves C1s to generate an active serine protease. Activated C1s cleaves C4 into C4a (a weak anaphylatoxin) and C4b, which covalently binds to the target surface via a thioester bond. C4b then recruits C2, which is cleaved by C1s into C2a (the catalytic subunit) and C2b, forming the classical C3 convertase C4b2a.

Lectin Pathway

The lectin pathway bypasses the need for antibodies altogether. It is initiated when mannose-binding lectin (MBL) or ficolins recognize conserved carbohydrate patterns—particularly terminal mannose, fucose, or N-acetylglucosamine residues—on microbial surfaces. MBL is structurally similar to C1q and associates with MBL-associated serine proteases (MASP-1 and MASP-2), which are functional homologs of C1r and C1s. Upon binding, MASP-2 cleaves C4 and C2 in exactly the same manner as activated C1s, generating the same C4b2a C3 convertase. Because microbial glycans differ systematically from mammalian glycans (which are typically capped with sialic acid), the lectin pathway provides pattern-based discrimination between self and non-self.

Alternative Pathway

The alternative pathway is unique in that it is constitutively active at a low level through a process called tick-over. In plasma, the thioester bond within native C3 undergoes spontaneous hydrolysis at a slow but constant rate, generating C3(H₂O), a conformationally altered form of C3 that can bind Factor B. Factor B in this complex is then cleaved by the serine protease Factor D into Ba (released) and Bb (retained), forming a fluid-phase C3 convertase C3(H₂O)Bb. This enzyme cleaves additional C3 to produce C3b, which can attach covalently to any nearby surface. On host cell surfaces, regulatory proteins (Factor H, MCP/CD46, DAF/CD55) rapidly inactivate deposited C3b. On microbial surfaces that lack these regulators, C3b associates with Factor B and Factor D to form the surface-bound alternative pathway C3 convertase C3bBb, which is stabilized by properdin (Factor P). This creates a powerful amplification loop.

Terminal Pathway: The Membrane Attack Complex

When a C3 convertase (either C4b2a or C3bBb) binds an additional C3b molecule, it becomes a C5 convertase (C4b2a3b or C3bBb3b). This enzyme cleaves C5 into C5a (the most potent anaphylatoxin) and C5b. C5b initiates assembly of the membrane attack complex (MAC). C5b sequentially binds C6, C7, and C8; the C5b-8 complex then recruits 10–16 molecules of C9, which polymerize to form a transmembrane pore approximately 10 nm in diameter. This pore disrupts the osmotic integrity of the target cell, leading to lysis. The MAC is particularly effective against Gram-negative bacteria, whose outer membrane is susceptible to pore formation, whereas Gram-positive bacteria are generally resistant due to their thick peptidoglycan layer.

Effector Functions & Regulatory Mechanisms

Left panel: the three major effector functions of complement (opsonization, inflammation, and cytolysis). Right panel: fluid-phase and membrane-bound regulators that protect host cells. Bottom: consequences of regulatory failure.
Key complement fragments and their biological functions
Complement FragmentFunctionReceptor / Target
C3bOpsonization; C5 convertase componentCR1 (CD35) on phagocytes
iC3bOpsonization (cannot form convertases)CR3 (CD11b/CD18), CR4
C3aAnaphylatoxin (mast cell degranulation)C3aR on mast cells, basophils
C5aPotent anaphylatoxin and chemotaxinC5aR (CD88) on neutrophils, macrophages
C5b–C9 (MAC)Transmembrane pore → osmotic lysisTarget cell membrane (esp. Gram-negative)
C3dEnhances B-cell activation (links innate to adaptive)CR2 (CD21) on B cells / FDCs

A particularly important bridge between innate and adaptive immunity is the role of C3d. When C3b on an antigen surface is successively degraded to iC3b and then to C3d, the C3d fragment remains covalently attached. When a B cell encounters this antigen, C3d simultaneously engages CR2 (CD21) in the B-cell co-receptor complex (CD19/CD21/CD81). This co-stimulatory signal lowers the threshold for B-cell activation by up to 1,000-fold, illustrating how complement directly modulates adaptive immune responses.

Worked Example: Tracing Complement Activation

Consider the following scenario: a patient with a confirmed Neisseria meningitidis (Gram-negative) bloodstream infection has IgM antibodies against the bacterial capsular polysaccharide. Trace the complement cascade from initiation to pathogen destruction and predict the effector outcomes.

Classical Pathway Activation Against N. meningitidis
1
Step 1 — Antibody Binding & C1 ActivationPentameric IgM binds capsular antigens on the surface of N. meningitidis. The Fc regions of the bound IgM are now exposed and accessible to C1q. Because pentameric IgM presents multiple Fc domains in close proximity, C1q engages at least two globular heads, triggering autoactivation of C1r, which activates C1s.
Active C1 complex (C1q:C1r₂:C1s₂) formed on bacterial surface
2
Step 2 — C4 and C2 Cleavage → C3 ConvertaseActive C1s cleaves C4 → C4a + C4b. The nascent C4b covalently attaches to the bacterial surface via its thioester bond. C2 binds to surface-associated C4b and is cleaved by C1s → C2a (enzymatic) + C2b (released). The resulting complex C4b2a is the classical pathway C3 convertase.
C3 convertase (C4b2a) assembled on N. meningitidis surface
3
Step 3 — C3 Cleavage & AmplificationC4b2a cleaves large numbers of C3 molecules → C3a (released as anaphylatoxin) + C3b (deposited on bacterial surface). Deposited C3b also recruits Factor B and Factor D to generate the alternative pathway convertase C3bBb, creating an amplification loop that massively increases C3b deposition. Because N. meningitidis lacks host regulatory proteins like DAF and Factor H, this amplification proceeds unchecked.
Bacterial surface heavily opsonized with C3b; C3a released into fluid phase
4
Step 4 — C5 Convertase → MAC AssemblyAn additional C3b molecule binds to the C3 convertase to form C4b2a3b (or C3bBb3b from the alternative loop), creating the C5 convertase. C5 is cleaved → C5a (potent anaphylatoxin and neutrophil chemoattractant) + C5b. C5b sequentially recruits C6, C7, C8, and 10–16 molecules of C9, which polymerize into the membrane attack complex (MAC). Because N. meningitidis is Gram-negative with an exposed outer membrane, the MAC inserts and forms a ~10 nm pore.
MAC pores form in outer membrane → osmotic lysis of N. meningitidis
5
Step 5 — Effector Outcomes SummaryThree concurrent effector arms are active: (1) C3b-mediated opsonization enhances phagocytosis by neutrophils bearing CR1 and CR3; (2) C3a and C5a trigger mast cell degranulation (histamine release, vasodilation) and recruit neutrophils to the site of infection; (3) MAC-mediated lysis directly kills the bacteria. This explains why patients with deficiencies in late complement components (C5–C9) are particularly susceptible to recurrent Neisseria infections.
Opsonization + Inflammation + Lysis = coordinated pathogen elimination

Comparing the Three Pathways

Side-by-side comparison of the three complement activation pathways
FeatureClassicalLectinAlternative
TriggerAntigen–antibody (IgG/IgM) complexesMannose/carbohydrate patterns on microbesSpontaneous C3 hydrolysis (tick-over)
Recognition moleculeC1qMBL, ficolinsC3(H₂O), then surface-bound C3b
Serine proteasesC1r, C1sMASP-1, MASP-2Factor D, Factor B
C3 convertaseC4b2aC4b2aC3bBb
C5 convertaseC4b2a3bC4b2a3bC3bBb3b
Antibody required?YesNoNo
Immune categoryAdaptive → Innate bridgeInnateInnate
Speed of responseSlower (requires antibody)ImmediateImmediate (always ticking over)
KEY TAKEAWAY
The three pathways represent an evolutionary layering of defense strategies. The alternative pathway—likely the most ancient—provides continuous, antibody-independent surveillance. The lectin pathway adds pattern-recognition specificity to this innate surveillance. The classical pathway integrates the specificity of antibodies with the destructive power of complement, effectively allowing the adaptive immune system to commandeer an innate effector cascade. Understanding which pathway is engaged first in a given infection helps predict the kinetics of complement-mediated defense and explains patterns of susceptibility in complement-deficient patients.

Complement Deficiencies & Therapeutic Targeting

The clinical importance of complement is most dramatically illustrated by complement deficiency syndromes. These genetic conditions reveal the non-redundant roles of specific complement components and have driven the development of complement-targeted therapies. The table below correlates deficiency with clinical phenotype, providing a framework for understanding how loss of specific complement functions translates to disease susceptibility.

Complement deficiencies and associated clinical phenotypes
Deficient ComponentPathway AffectedClinical Consequence
C1q, C2, or C4ClassicalSystemic lupus erythematosus (SLE)-like disease; impaired immune complex clearance
MBLLectinIncreased susceptibility to infections in early childhood (before adaptive immunity matures)
C3All pathwaysSevere, recurrent pyogenic (pus-forming) infections; impaired opsonization
C5, C6, C7, C8, or C9Terminal / MACRecurrent Neisseria infections (meningococcal/gonococcal); cannot form MAC
Factor H or Factor IAlternative (regulation)Atypical hemolytic uremic syndrome (aHUS); uncontrolled C3b deposition on host endothelium
DAF (CD55) + CD59All (regulation)Paroxysmal nocturnal hemoglobinuria (PNH): complement-mediated lysis of own RBCs
C1 inhibitor (C1-INH)Classical (and kinin)Hereditary angioedema (HAE); uncontrolled C1 activation and bradykinin generation
💊 Therapeutic Milestone: Eculizumab
Eculizumab (Soliris®) is a humanized monoclonal antibody that binds C5 and blocks its cleavage into C5a and C5b. By preventing MAC formation and C5a-mediated inflammation, eculizumab has transformed the treatment of PNH and aHUS. However, because it eliminates MAC-mediated killing, patients on eculizumab must be vaccinated against Neisseria meningitidis to reduce the risk of life-threatening meningococcal disease. Newer complement therapeutics target other nodes—Factor D inhibitors, C3 inhibitors (e.g., pegcetacoplan), and Factor B inhibitors—expanding the complement pharmacopeia.

Beyond genetic deficiencies, complement dysregulation is implicated in a growing list of conditions including age-related macular degeneration (Factor H polymorphisms), transplant rejection (antibody-mediated complement activation on graft endothelium), and even neurodegenerative diseases where complement-mediated synaptic pruning goes awry. As our understanding of complement biology deepens, the system has transitioned from a textbook curiosity to a major therapeutic target in modern medicine.

Practice Problems

PROBLEM 1CONCEPTUAL
All three complement activation pathways converge at the cleavage of a single, central component. Identify this component and explain why convergence at this point is advantageous for host defense.
PROBLEM 2BASIC CALCULATION
If a single C3 convertase can cleave approximately 200 C3 molecules per minute, and each deposited C3b can generate one new alternative pathway C3 convertase (C3bBb), estimate the total number of C3b molecules deposited after 2 minutes, starting from one initial C3 convertase. Assume each new convertase begins cleaving in the next minute and ignore regulatory degradation.
PROBLEM 3INTERMEDIATE
A patient presents with recurrent episodes of meningococcal meningitis. Laboratory testing reveals normal C3 and C4 levels but undetectable hemolytic complement activity (CH50 = 0). Which complement component(s) are most likely deficient, and why does this specific deficiency predispose to Neisseria infections while leaving other complement functions intact?
PROBLEM 4APPLIED
A researcher is designing an experiment to test whether a novel bacterial surface protein inhibits complement activation. She incubates wild-type bacteria and mutant bacteria (lacking the surface protein) with normal human serum and measures C3b deposition by flow cytometry. Predict the expected results and describe two additional assays she should perform to determine which pathway the bacterial protein is inhibiting.
PROBLEM 5CRITICAL THINKING
Eculizumab blocks C5 cleavage, preventing MAC formation and C5a generation. Propose a mechanistic argument for why a C3 inhibitor (such as compstatin/pegcetacoplan) might be more efficacious than eculizumab for certain diseases, but also explain a major safety concern that a C3 inhibitor would introduce that eculizumab does not.

Complement System — Summary

The complement system is a proteolytic cascade of over 30 proteins that provides rapid, amplified antimicrobial defense. Three activation pathways—classical (triggered by antigen–antibody complexes via C1q), lectin (triggered by MBL binding microbial carbohydrates), and alternative (constitutive tick-over of C3)—all converge at the cleavage of C3 into C3a and C3b. The alternative pathway amplification loop generates massive C3b deposition on pathogen surfaces, enabling three key effector outcomes: opsonization for phagocytosis, anaphylatoxin-mediated inflammation (C3a, C5a), and membrane attack complex (MAC) lysis via C5b–C9.

Host cells are protected by regulatory proteins including DAF (CD55), MCP (CD46), CD59, and Factor H. Deficiencies in early classical components predispose to SLE-like autoimmunity; C3 deficiency causes severe pyogenic infections; terminal component deficiencies lead to recurrent Neisseria infections; and regulatory defects cause PNH and aHUS. Therapeutically, eculizumab (anti-C5) and pegcetacoplan (C3 inhibitor) exemplify how targeting specific nodes of the cascade can treat complement-mediated diseases while balancing the trade-off of increased infection risk.

Varsity Tutors • Microbiology • Complement System